{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:45:17Z","timestamp":1790995517359,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bioorg.2026.109562","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:08:56Z","timestamp":1769818136000},"page":"109562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rational design of 2-substituted thio-7-chloroquinazolin-4(3H)-one derivatives as dual EGFR\/VEGFR-2 inhibitors with broad-Spectrum anticancer and apoptotic activities"],"prefix":"10.1016","volume":"172","author":[{"given":"Mostafa A.","family":"Mansour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar H.","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa M.","family":"AboulMagd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamdy M.","family":"Abdel-Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abdel-Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.bioorg.2026.109562_bb0005","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1002\/cncr.33587","article-title":"The ever-increasing importance of cancer as a leading cause of premature death worldwide","volume":"127","author":"Bray","year":"2021","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109562_bb0010","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3390\/cancers14040976","article-title":"Dissecting tumor growth: the role of cancer stem cells in drug resistance and recurrence","volume":"14","author":"Aramini","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109562_bb0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12943-025-02250-9","article-title":"Towards understanding cancer dormancy over strategic hitching up mechanisms to technologies","volume":"24","author":"Yang","year":"2025","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.bioorg.2026.109562_bb0020","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00018-022-04348-5","article-title":"Biological aspects in controlling angiogenesis: current progress","volume":"79","author":"Akbarian","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109562_bb0025","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/mco2.55","article-title":"Molecular mechanisms of chemo-and radiotherapy resistance and the potential implications for cancer treatment","volume":"2","author":"Liu","year":"2021","journal-title":"MedComm"},{"key":"10.1016\/j.bioorg.2026.109562_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1366260","article-title":"Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges","volume":"15","author":"Xiang","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109562_bb0035","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109562_bb0040","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2284113","article-title":"9, 10-Dioxoanthracenyldithiocarbamates effectively inhibit the proliferation of non-small cell lung cancer by targeting multiple protein tyrosine kinases","volume":"39","author":"Olszewski","year":"2024","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"27","key":"10.1016\/j.bioorg.2026.109562_bb0045","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1039\/D3RA02347H","article-title":"Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review","volume":"13","author":"Mansour","year":"2023","journal-title":"RSC Adv."},{"issue":"22","key":"10.1016\/j.bioorg.2026.109562_bb0050","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.3390\/cells13221838","article-title":"Apoptosis: a comprehensive overview of signaling pathways, morphological changes, and physiological significance and therapeutic implications","volume":"13","author":"Mustafa","year":"2024","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109562_bb0055","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3390\/molecules26041076","article-title":"Molecular targeting of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR)","volume":"26","author":"Kaufman","year":"2021","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.bioorg.2026.109562_bb0060","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.3390\/cancers13112748","article-title":"EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance","volume":"13","author":"Uribe","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.bioorg.2026.109562_bb0065","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3390\/cancers16101794","article-title":"Angiogenesis still plays a crucial role in human melanoma progression","volume":"16","author":"Cazzato","year":"2024","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.bioorg.2026.109562_bb0070","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109562_bb0075","first-page":"271","article-title":"Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer","volume":"39","author":"Brave","year":"2011","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109562_bb0080","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/14756366.2020.1715389","article-title":"Design, synthesis and in vitro biological evaluation of quinazolinone derivatives as EGFR inhibitors for antitumor treatment","volume":"35","author":"Le","year":"2020","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109562_bb0085","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/molecules23010024","article-title":"Design and discovery of quinazoline-and thiourea-containing sorafenib analogs as EGFR and VEGFR-2 dual TK inhibitors","volume":"23","author":"Sun","year":"2017","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.bioorg.2026.109562_bb0090","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1517\/13543784.12.8.1395","article-title":"Erlotinib: a new therapeutic approach for non-small cell lung cancer","volume":"12","author":"Bonomi","year":"2003","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"7","key":"10.1016\/j.bioorg.2026.109562_bb0095","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1634\/theoncologist.10-7-461","article-title":"FDA drug approval summary: erlotinib (Tarceva\u00ae) tablets","volume":"10","author":"Cohen","year":"2005","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109562_bb0100","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1080\/14756366.2019.1593160","article-title":"Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile","volume":"34","author":"Mghwary","year":"2019","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109562_bb0105","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3389\/fchem.2019.00917","article-title":"Novel anticancer fused pyrazole derivatives as EGFR and VEGFR-2 dual TK inhibitors","volume":"7","author":"Saleh","year":"2020","journal-title":"Front. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2026.109562_bb0110","first-page":"4645","article-title":"ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration","volume":"62","author":"Wedge","year":"2002","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109562_bb0115","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","article-title":"Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"28","author":"Wells","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bioorg.2026.109562_bb0120","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201700240","article-title":"Design, synthesis, molecular docking, and anticancer activity of phthalazine derivatives as VEGFR-2 inhibitors","volume":"350","author":"El-Helby","year":"2017","journal-title":"Arch. Pharm."},{"issue":"24","key":"10.1016\/j.bioorg.2026.109562_bb0125","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-06-1249","article-title":"Sorafenib for the treatment of advanced renal cell carcinoma","volume":"12","author":"Kane","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109562_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106791","article-title":"New quinazoline sulfonamide derivatives as potential anticancer agents: identifying a promising hit with dual EGFR\/VEGFR-2 inhibitory and radiosensitizing activity","volume":"140","author":"Ghorab","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109562_bb0135","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.14534","article-title":"Structural and molecular insights from dual inhibitors of EGFR and VEGFR2 as a strategy to improve the efficacy of cancer therapy","volume":"103","author":"Budipramana","year":"2024","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2026.109562_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119531","article-title":"EGFR\/VEGFR-2 dual inhibitor and apoptotic inducer: design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives","volume":"277","author":"Mourad","year":"2021","journal-title":"Life Sci."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109562_bb0145","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1021\/acs.jmedchem.9b01541","article-title":"Urea derivatives in modern drug discovery and medicinal chemistry","volume":"63","author":"Ghosh","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109562_bb0150","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejmech.2014.02.005","article-title":"Recent advances in the structural library of functionalized quinazoline and quinazolinone scaffolds: synthetic approaches and multifarious applications","volume":"76","author":"Khan","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109562_bb0155","article-title":"Synthesis of medicinally important quinazolines and their derivatives: a review","volume":"14","author":"Sharma","year":"2020","journal-title":"The Open Medicinal Chem. J."},{"key":"10.1016\/j.bioorg.2026.109562_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2013.10.058","article-title":"Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors","volume":"71","author":"de Castro Barbosa","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109562_bb0165","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/ddr.21925","article-title":"An appraisal of anticancer activity with structure\u2013activity relationship of quinazoline and quinazolinone analogues through EGFR and VEGFR inhibition: a review","volume":"83","author":"Haider","year":"2022","journal-title":"Drug Dev. Res."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109562_bb0170","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ardp.201400337","article-title":"Design, synthesis and in vitro antiproliferative activity of novel isatin-quinazoline hybrids","volume":"348","author":"Fares","year":"2015","journal-title":"Arch. Pharm."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109562_bb0175","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1016\/j.bmcl.2013.03.107","article-title":"Synthesis, single crystal and antitumor activities of benzimidazole\u2013quinazoline hybrids","volume":"23","author":"Sharma","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.bioorg.2026.109562_bb0180","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.bmcl.2016.02.053","article-title":"Effect of chlorine substituent on cytotoxic activities: design and synthesis of systematically modified 2, 4-diphenyl-5H-indeno [1, 2-b] pyridines","volume":"26","author":"Kadayat","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109562_bb0185","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2174\/1573406415666190613162322","article-title":"Synthesis, anticancer activity on prostate cancer cell lines and molecular modeling studies of flurbiprofen-thioether derivatives as potential target of MetAP (type II)","volume":"16","author":"Y\u0131lmaz","year":"2020","journal-title":"Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109562_bb0190","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/14756366.2013.763253","article-title":"Synthesis and anticancer activity evaluation of N-[4-(2-methylthiazol-4-yl) phenyl] acetamide derivatives containing (benz) azole moiety","volume":"29","author":"Yurtta\u015f","year":"2014","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2026.109562_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241311044","article-title":"Design, synthesis, and biological evaluation of novel Quinazolin-4 (3H)-one-based histone deacetylase 6 (HDAC6) inhibitors for anticancer activity","volume":"24","author":"Khetmalis","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"52","key":"10.1016\/j.bioorg.2026.109562_bb0200","doi-asserted-by":"crossref","first-page":"38403","DOI":"10.1039\/D4RA06694D","article-title":"Design, synthesis, and antiproliferative activity of new 1, 2, 3-triazole\/quinazoline-4-one hybrids as dual EGFR\/BRAF V600E inhibitors","volume":"14","author":"Mohamed","year":"2024","journal-title":"RSC Adv."},{"issue":"9","key":"10.1016\/j.bioorg.2026.109562_bb0205","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202100051","article-title":"Design, synthesis, and pharmacological characterization of some 2-substituted-3-phenyl-quinazolin-4 (3H)-one derivatives as phosphodiesterase inhibitors","volume":"354","author":"Amin","year":"2021","journal-title":"Arch. Pharm."},{"issue":"44","key":"10.1016\/j.bioorg.2026.109562_bb0210","doi-asserted-by":"crossref","first-page":"30753","DOI":"10.1039\/D3RA05310E","article-title":"Pyrrolizine\/indolizine-bearing (un) substituted isoindole moiety: design, synthesis, antiproliferative and MDR reversal activities, and in silico studies","volume":"13","author":"AbdelSamad","year":"2023","journal-title":"RSC Adv."},{"issue":"13","key":"10.1016\/j.bioorg.2026.109562_bb0215","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1016\/j.bmc.2016.05.019","article-title":"Synthesis and structure\u2013activity relationships of novel hybrid ferrocenyl compounds based on a bicyclic core skeleton for breast cancer therapy","volume":"24","author":"Li","year":"2016","journal-title":"Bioorg. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2026.109562_bb0220","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1007\/s00044-016-1658-z","article-title":"Strategic synthesis and in vitro antimicrobial evaluation of novel difluoromethylated 1-(1, 3-diphenyl-1 H-pyrazol-4-yl)-3, 3-difluoro-1, 3-dihydro-indol-2-ones","volume":"25","author":"Chundawat","year":"2016","journal-title":"Med. Chem. Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109562_bb0225","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1080\/14756366.2022.2118735","article-title":"Design and synthesis of novel quinazolinone-based derivatives as EGFR inhibitors with antitumor activity","volume":"37","author":"Sonousi","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109562_bb0230","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1080\/14756366.2017.1344981","article-title":"Synthesis, anticancer and apoptosis-inducing activities of quinazoline\u2013isatin conjugates: epidermal growth factor receptor-tyrosine kinase assay and molecular docking studies","volume":"32","author":"El-Azab","year":"2017","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109562_bb0235","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.ejmech.2017.12.009","article-title":"Synthesis and antibacterial evaluation of novel cationic chalcone derivatives possessing broad spectrum antibacterial activity","volume":"143","author":"Chu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109562_bb0240","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ejmech.2017.06.020","article-title":"2-substituted-thio-N-(4-substituted-thiazol\/1H-imidazol-2-yl) acetamides as BACE1 inhibitors: synthesis, biological evaluation and docking studies","volume":"137","author":"Yan","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109562_bb0245","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/00397910701845852","article-title":"Synthesis of 2-(5-Substituted-1, 3, 4-thiadiazolo-2-ylimino)-4-thiazolidinones under microwave irradiation","volume":"38","author":"Wang","year":"2008","journal-title":"Synth. Commun."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109562_bb0250","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00044-020-02683-5","article-title":"Design, synthesis, docking study and urease inhibitory activity evaluation of novel 2-((5-amino-1, 3, 4-thiadiazol-2-yl) thio)-N-arylacetamide derivatives","volume":"30","author":"Nazari Montazer","year":"2021","journal-title":"Med. Chem. Res."},{"issue":"25","key":"10.1016\/j.bioorg.2026.109562_bb0255","doi-asserted-by":"crossref","first-page":"17074","DOI":"10.1039\/D3RA00446E","article-title":"Design, synthesis, and biological evaluation with molecular dynamics study of novel pyrazolo [3, 4-d] pyrimidine derivatives as anti-cancer agents","volume":"13","author":"Shaban","year":"2023","journal-title":"RSC Adv."},{"issue":"10","key":"10.1016\/j.bioorg.2026.109562_bb0260","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrc1951","article-title":"The NCI60 human tumour cell line anticancer drug screen","volume":"6","author":"Shoemaker","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109562_bb0265","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ddr.430340203","article-title":"Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen","volume":"34","author":"Boyd","year":"1995","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bioorg.2026.109562_bb0270","series-title":"An overview of colorimetric assay methods used to assess survival or proliferation of mammalian cells","author":"Vega-Avila","year":"2011"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109562_bb0275","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202300626","article-title":"Quinazoline-chalcone hybrids as HDAC\/EGFR dual inhibitors: design, synthesis, mechanistic, and in-silico studies of potential anticancer activity against multiple myeloma","volume":"357","author":"Mansour","year":"2024","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2026.109562_bb0280","series-title":"Drug Design and Discovery: Methods and Protocols","first-page":"157","article-title":"Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability","author":"Sylvester","year":"2011"},{"issue":"8","key":"10.1016\/j.bioorg.2026.109562_bb0285","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/iub.1188","article-title":"Caffeic acid phenethyl ester synergistically enhances docetaxel and paclitaxel cytotoxicity in prostate cancer cells","volume":"65","author":"Tolba","year":"2013","journal-title":"IUBMB Life"},{"key":"10.1016\/j.bioorg.2026.109562_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.134583","article-title":"Design, synthesis and mechanistic studies of benzophenones hydrazone derivatives as cathepsin inhibitors","volume":"1274","author":"Abdel-Azziz","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.109562_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106143","article-title":"Novel 1, 3-diaryl pyrazole derivatives bearing methylsulfonyl moiety: design, synthesis, molecular docking and dynamics, with dual activities as anti-inflammatory and anticancer agents through selectively targeting COX-2","volume":"129","author":"Shaker","year":"2022","journal-title":"Bioorg. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109562_bb0300","first-page":"1172","article-title":"Novel sigma 1-antagonists with cis-(+)-normetazocine scaffold: synthesis, molecular modeling, and antinociceptive effect","volume":"16","author":"Costanzo","year":"2025"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109562_bb0305","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2174\/0115734099266822231219073332","article-title":"EGFR kinase inhibiting amino-enones for breast Cancer; CADD Approach","volume":"21","author":"Mohanraj","year":"2025","journal-title":"Current Comput.-Aided Drug Design"},{"key":"10.1016\/j.bioorg.2026.109562_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1534707","article-title":"Pharmacophore screening, molecular docking, and MD simulations for identification of VEGFR-2 and c-met potential dual inhibitors","volume":"16","author":"Dong","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"56","key":"10.1016\/j.bioorg.2026.109562_bb0315","doi-asserted-by":"crossref","first-page":"34033","DOI":"10.1039\/D0RA06424F","article-title":"Quinazoline-Schiff base conjugates: in silico study and ADMET predictions as multi-target inhibitors of coronavirus (SARS-CoV-2) proteins","volume":"10","author":"Mansour","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.109562_bb0320","series-title":"Novel Benzimidazole Hybrids: Design, Synthesis, Mechanistic Studies, Antifungal Potential and Molecular Dynamics","author":"Ibrahim","year":"2025"},{"key":"10.1016\/j.bioorg.2026.109562_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105687","article-title":"Design, synthesis, biological assessment, and in-silico studies of 1, 2, 4-triazolo [1, 5-a] pyrimidine derivatives as tubulin polymerization inhibitors","volume":"121","author":"Mohamed","year":"2022","journal-title":"Bioorg. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826000982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826000982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:57:22Z","timestamp":1784753842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826000982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":65,"alternative-id":["S0045206826000982"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109562","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rational design of 2-substituted thio-7-chloroquinazolin-4(3H)-one derivatives as dual EGFR\/VEGFR-2 inhibitors with broad-Spectrum anticancer and apoptotic activities","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109562","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109562"}}